Outcomes of ovarian stimulation and fertility preservation in breast cancer patients with different hormonal receptor profiles

被引:12
|
作者
Balayla, Jacques [1 ]
Tulandi, Togas [1 ]
Buckett, William [1 ]
Holzer, Hananel [1 ,2 ]
Steiner, Naama [1 ]
Shrem, Guy [1 ]
Volodarsky-Perel, Alexander [1 ,3 ]
机构
[1] McGill Univ, Dept Obstet & Gynecol, 1001 Decarie Blvd, Montreal, PQ H4A 3J1, Canada
[2] Hadassah Med Ctr, Dept Obstet & Gynecol, IL-91120 Jerusalem, Israel
[3] Jewish Gen Hosp, Lady Davis Res Inst, 3755 Chemin Cote St Catherine, Montreal, PQ H3T 1E2, Canada
关键词
Triple-negative breast cancer; Fertility preservation; Number of oocytes; Estrogen receptor; Progesterone receptor; EMBRYO-TRANSFER; LIVE BIRTH; WOMEN; ESTROGEN; TAMOXIFEN; ASSOCIATION; EXPRESSION; MUTATIONS; FEATURES; IMPACT;
D O I
10.1007/s10815-020-01730-9
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Purpose To evaluate fertility preservation outcomes in breast cancer women with different hormonal receptor profiles before oncological treatment. Methods The study population included women with a diagnosis of breast cancer who underwent fertility preservation from 2009 until 2018 at a university-affiliated tertiary hospital. Stimulation parameters and fertility preservation outcomes were compared among the following receptor-specific profile groups: (1) estrogen receptor positive (ER+) versus estrogen receptor negative (ER-), (2) triple-negative breast cancer (TNBC) versus estrogen and progesterone receptor positive (ER+/PR+), and (3) TNBC versus non-TNBC. Primary outcome was the total number of mature oocytes. Secondary outcomes included the number of retrieved oocytes, the peak estradiol level, and the number of follicles > 14 mm on the final oocyte maturation trigger day. Results A total of 155 cycles were included in the final analysis. These were divided into the exposure groups of ER+ (n = 97), ER- (n = 58), ER+/PR+ (n = 85), TNBC (n = 57), and non-TNBC (n = 98). Cycle outcomes revealed similar number of retrieved oocytes and follicles > 14 mm on the trigger day. Women with TNBC had significantly lower number of mature oocytes compared with those with ER + PR+ (7 (5-11) versus 9 (7-15); p = 0.02) and non-TNBC (7 (5-11) versus 9 (7-16); p = 0.01) status. Triple-negative breast cancer profile was associated with a significant reduction in the chance of developing over 10 mature oocytes (OR 0.41; 95% CI 0.19-0.92). Conclusion Among the different hormonal receptor profiles in breast cancer, the TNBC subtype has a negative effect on fertility preservation outcomes.
引用
收藏
页码:913 / 921
页数:9
相关论文
共 50 条
  • [1] Outcomes of ovarian stimulation and fertility preservation in breast cancer patients with different hormonal receptor profiles
    Jacques Balayla
    Togas Tulandi
    William Buckett
    Hananel Holzer
    Naama Steiner
    Guy Shrem
    Alexander Volodarsky-Perel
    Journal of Assisted Reproduction and Genetics, 2020, 37 : 913 - 921
  • [2] Ovarian stimulation response and fertility outcomes in patients with breast cancer across different stages, grades, and hormone receptor status for fertility preservation
    Liu, Shang-Min
    Huang, Shang-Yu
    Wu, Hsien-Ming
    Chang, Chia-Lin
    Huang, Hong-Yuan
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2025, 124 (03) : 241 - 245
  • [3] Impact of letrozole supplementation during ovarian stimulation for fertility preservation in breast cancer patients
    Sonigo, Charlotte
    Sermondade, Nathalie
    Calvo, Jeremy
    Benard, Julie
    Sifer, Christophe
    Grynberga, Michael
    EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY-X, 2019, 4
  • [4] Effects of cancer stage and grade on fertility preservation outcome and ovarian stimulation response
    Volodarsky-Perel, Alexander
    Cohen, Yoni
    Arab, Suha
    Son, Weon-Young
    Suarthana, Eva
    Dahan, Michael Haim
    Tulandi, Togas
    Buckett, William
    HUMAN REPRODUCTION, 2019, 34 (03) : 530 - 538
  • [5] Ovarian stimulation for fertility preservation in patients with cancer
    Quintero, Rudolpho B.
    Helmer, Amy
    Huang, Jian Qun
    Westphal, Lynn M.
    FERTILITY AND STERILITY, 2010, 93 (03) : 865 - 868
  • [6] Maximize the safety and efficacy of fertility preservation by random start/dual ovarian stimulation for early breast cancer patients
    Young, Shih-Hung Richard
    Chang, Yi-En
    Yang, Wei-Chung Vivian
    Lu, Buo-Jia
    Chou, Szu-Yuan
    Chen, Chi -Huang
    TAIWANESE JOURNAL OF OBSTETRICS & GYNECOLOGY, 2023, 62 (02): : 330 - 333
  • [7] Progesterone levels in letrozole associated controlled ovarian stimulation for fertility preservation in breast cancer patients
    Goldrat, O.
    Gervy, C.
    Englert, Y.
    Delbaere, A.
    Demeestere, I.
    HUMAN REPRODUCTION, 2015, 30 (09) : 2184 - 2189
  • [8] Hereditary breast cancer and fertility preservation outcomes
    Arab, Suha
    Tulandi, Togas
    Buckett, William
    JOURNAL OF ASSISTED REPRODUCTION AND GENETICS, 2022, 39 (05) : 1163 - 1168
  • [9] Fertility preservation in breast cancer patients: IVF and embryo cryopreservation after ovarian stimulation with tamoxifen
    Oktay, K
    Buyuk, E
    Davis, O
    Yermakova, I
    Veeck, L
    Rosenwaks, Z
    HUMAN REPRODUCTION, 2003, 18 (01) : 90 - 95
  • [10] Fertility outcomes several years after urgent fertility preservation for patients with breast cancer
    Peigne, Mealiss
    Mur, Pauline
    Laup, Laetitia
    Hamy, Anne-Sophie
    Sifer, Christophe
    Mayeur, Anne
    Eustache, Florence
    Sarandi, Solmaz
    Vinolas, Claire
    Rakrouki, Sophia
    Benoit, Alexandra
    Grynberg, Michael
    Sonigo, Charlotte
    FERTILITY AND STERILITY, 2024, 122 (03) : 504 - 513